科研之友
微信
新浪微博
Facebook
分享链接
摘要
Objective To investigate the effect of reverse add therapy with gonadotropin releasing hormone agonist ( GnRHa ) combined with estradiol valerate on serum levels of cancer embryo antigen CA125, vascular endothelial growth factor ( VEGF) and recurrence of severe endometriosis ( EMs) patients . Methods 90 patients with severe EMs treated in Foshan Fifth People 's Hospital from May 2013 to May 2014 were randomly divided into two groups after conservative laparoscopic surgery. The control group was injected with GnRHa,and GnRHa combined with estradiol valerate was used in the research group. Compare the efficacy of the two groups, the levels of CA125 and VEGF, the incidence of adverse reaction and recurrence. Results Total effective rate of the two groups was compared after treatment (92. 86% vs 78. 57%). There was no significant difference (P> 0. 05). After treatment, the levels of CA125 and VEGF in both groups were significantly lower than before treatment (P <0. 05). But the difference between the two groups were not statistically significant (P> 0. 05). After treatment, incidence rate of side effects such as hectic fever and sweating, insomnia, joint pain, vaginal dryness, sexual life disorder and abnormal emotion in the research group were significantly lower than that of the control group. The difference was statistically significant (P <0. 05). After two years of follow-up,recurrence rates of the two groups were compared and the difference was not statistically significant ( P> 0. 05 ) . Conclusion GnRHa can decrease the level of CA125 and VEGF in patients with severe EMs after conservative laparoscopic surgery with high curative effect, but the incidence of side effects is also high. GnRHa combined with estradiol valerate therapy has no significant effect on curative effect and relapse rate, but it can significantly reduce the incidence of side effects and improve the quality of life of patients with low estrogen levels.
